Context Therapeutics Inc. · NASDAQ:CNTX

Context Therapeutics — Investor Presentation (March 2024)

23 slides from Context Therapeutics's investor presentation, Mar 6, 2024

1. Slide 1: Corporate Presentation: Advancing Medicines for Solid Tumors

   March 2024 Corporate Presentation Advancing Medicines for Solid Tumors

2. Slide 2: Important Notice and Disclaimers

   Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances

3. Slide 3: Executive Summary: Lead Program CTIM-76, a CLDN6 x CD3 Bispecific Antibody

   Lead Program: CTIM-76, a Claudin 6 (CLDN6) x CD3 Bispecific Antibody Executive Summary Context Therapeutics Inc. - March 20243 Lead Asset CTIM-76 is a potentially best-in-class CLDN6 T cell engaging (TCE) bispecific antibody • CLDN6 enriched in a wide range of cancers, but absent or expressed at low

4. Slide 4: CTIM-76: Claudin x CD3 T cell Engaging Bispecific Antibody

   CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Established bispecific format • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functionally monovalent to avoid aberrant T-cell activ

5. Slide 5: CLDN6 Clinical Proof of Concept in Ovarian and Testicular Cancers

   CLDN6 Clinical Proof of Concept in Ovarian and Testicular Cancers Executive Summary Context Therapeutics Inc. - March 20245 BNT211 (CLDN6 CART) TORL-1-23 (CLDN6 ADC) Cutoff Date September 10, 20231 September 29, 20232 Patients (n) 44 (38 evaluable) Ovarian = 17 Testicular = 16 Other =11 42 (36 evalu

6. Slide 6: TCE Bispecific Data Targeting DLL3, PSMA, and STEAP1

   TCE Bispecific Data Targeting DLL3, PSMA, and STEAP1 Recent data supports promising efficacy with low rate of ≥ G3 cytokine release syndrome (CRS) Asset Tarlatamab (AMG757) HPN328 JANX007 Xaluritamig (AMG509) Target DLL3 x CD3 DLL3 x CD3 PSMA x CD3 STEAP1 x CD3 Indication Small Cell Lung Cancer (SCL

7. Slide 7: Claudin 6 (CLDN6) Target biology and therapeutic rationale

   Claudin 6 (CLDN6) Target biology and therapeutic rationale Context Therapeutics Inc. - March 20247

8. Slide 8: CLDN6 is an Oncofetal Protein

   CLDN6 is an Oncofetal Protein Oncofetal proteins are considered favorable candidates for immunotherapy • Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Increased expression known to occur in some tumor cells, including

9. Slide 9: CLDN6 Has the Potential to Reach a Large Patient Population

   CLDN6 Has the Potential to Reach a Large Patient Population >50,000 patients per year in the US only in Relapse/Refractory (R/R) Setting CLDN6 Target Biology 9 Context Therapeutics Inc. - March 2024 Initial indications of interest based on: • CLDN6 prevalence • Patient population size • Observed cli

10. Slide 10: CLDN6 is Selectively Expressed on Cancer Cells

    CLDN6 is Selectively Expressed on Cancer Cells CLDN6 Target Biology Context Therapeutics Inc. - March 202410 (a) adrenal gland, (b) fallopian tube, (c) kidney, (d) liver, (e) thyroid, (f) prostate, (g) esophagus, (h) stomach, (i) colon, (j) cerebrum, (k) cerebellum, (l) spinal cord. (m) thymus, (n)

11. Slide 11: High CLDN6 Associated with a Worsened Prognosis in Cancer Patients

    High CLDN6 Associated with a Worsened Prognosis in Cancer Patients CLDN6 Target Biology Context Therapeutics Inc. - March 202411 Endometrial Cancer1 Overexpression of CLDN6 is associated with worse overall survival in endometrial cancer patients 1 Kojima, Cancers, 2020; 2 Zhang, Front. Cell Dev. Bio

12. Slide 12: CLDN6 Has Limited Overlap with Competing Targets for Female Reproductive Cancers

    CLDN6 Has Limited Overlap with Competing Targets for Female Reproductive Cancers CLDN6 Target Biology Context Therapeutics Inc. - March 202412 Bishop, AnalyzeR [Data Set] Accessed March 1, 2024 Female Reproductive Cancer Correlation between CLDN6 and other targets via RNAseq biopsy data CLDN6 vs. FR

13. Slide 13: CTIM-76 Claudin x CD3 Development Candidate

    CTIM-76 Claudin 6 x CD3 Development Candidate Context Therapeutics Inc. - March 202413

14. Slide 14: Developing a Highly Selective CLDN6 Antibody is Challenging

    Developing a Highly Selective CLDN6 Antibody is Challenging CTIM-76 Program Context Therapeutics Inc. - March 202414 CLDN9 CLDN6 CLDN4 CLDN3 CLDN5 CLDN8 CLDN17 CLDN2 CLDN14 CLDN20 CLDN7 CLDN1 CLDN19 CLDN34 CLDN12 CLDN23 CLDN16 CLDN24 CLDN22 CLDN25 CLDN18 CLDN11 CLDN15 CLDN10 • CLDN6 antigen is confo

15. Slide 15: CTIM-76: T cell engaging CLDN6 x CD3 Bispecific Antibody

    CTIM-76 Program CTIM-76: T cell engaging (TCE) CLDN6 x CD3 Bispecific Antibody Context Therapeutics Inc. - March 202415 Selectivity Potency In Vivo Efficacy • CTIM-76 CLDN6 EC50 of 3.41 nM (binding) • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently transfected in

16. Slide 16: Competitive Landscape

    Competitive Landscape 16 Context Therapeutics Inc. - March 2024

17. Slide 17: CLDN6 Competitive Landscape Strategy

    CLDN6 Competitive Landscape Strategy Assets in Development Assets in the Clinic Characteristics Bispecific 7 3 • Weak internalization makes CLDN6 ideal for bispecific targeting • Selective expression in cancer cells potentially mitigates CRS risk • Potential to address low-to-high CLDN6 expression d

18. Slide 18: CLDN6 Competitive Landscape

    CLDN6 Competitive Landscape1 Context Therapeutics Inc. - March 202418 Scalable Manufacturing Process Complex Manufacturing Process Potential / Disclosed Safety Liabilities Selectivity for CLDN6 vs CLDN3,4,9 Limited Information on Asset Limited Selectivity Deprioritized CLDN6-CAR-NK CAR-NK + IL7 FPI

19. Slide 19: CLDN6 x CD3 T Cell Engaging Bispecifics Competitive Landscape

    CLDN6 x CD3 T Cell Engaging Bispecifics Competitive Landscape Context Therapeutics Inc. - March 202419 CTIM-76 XmAb541 AMG794 SAIL66 NBL-028 Beigene Company Context Xencor Amgen Chugai NovaRock Beigene Stage IND Q1 20241 IND Dec 2023 Ph 1 Ph 1 Ph 1 IND Dec 2023 Bispecific Format 1 + 1 2 + 1 HLE Bite

20. Slide 20: Corporate

    Corporate 20 Context Therapeutics Inc. - March 2024

21. Slide 21: Experienced Leadership Team

    Corporate Experienced Leadership Team • Experienced team • Our management team is supported by a Board with strong public company operating and governance experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Jennifer Minai, CPA Chief Financial Officer Chris

22. Slide 22: Corporate Investment Highlights

    Corporate Investment Highlights (Nasdaq: CNTX) Solid Tumors Large Unmet Need Claudin 6 High-Value Target On track for end of March 2024 IND Filing Milestones Oncology preclinical and clinical experience Strong Team Expected Cash Runway into late 2024 Cash Runway Context Therapeutics Inc. - March 202

23. Slide 23: Advancing Medicines for Solid Tumors

    Advancing Medicines for Solid Tumors © Context Therapeutics 2024

Context Therapeutics — Investor Presentation (March 2024) on 6ix